Company to present data sets from recently launched high-parameter,
spatial biology imaging platforms for discovery through clinical and
translational research
MENLO PARK, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/AACR19?src=hash" target="_blank"gt;#AACR19lt;/agt;–Akoya Biosciences, Inc., today announced that data from its new line of
multiplex immunofluorescence imaging platforms for high-parameter,
spatially resolved biomarker analysis will be presented at the upcoming
American Association for Cancer Research (AACR) Annual Meeting 2019. The
meeting runs March 29 – April 3, 2019 in Atlanta, Georgia.
The company will feature data from its new products in an Exhibitor
Spotlight Theater presentation on Sunday, March 31, from 1:30-2:30 PM
titled “Pushing the frontiers of immuno-oncology with multiplex
immunofluorescence” with speakers David Rimm, MD, PhD, Professor of
Pathology at Yale University School of Medicine and Julia
Kennedy-Darling, PhD, Director of R&D at Akoya Biosciences. During the
presentation, Dr. Rimm will discuss the results from a
Multi-institutional TSA-amplified Multiplexed Immunofluorescence
Reproducibility Evaluation (MITRE Study) which assessed the
reproducibility of Akoya’s automated multiplexed immunofluorescence
slide staining, imaging, and analysis workflow.
“The exciting results from our MITRE Study demonstrate that multiplexed
immunofluorescence methods can be analytically robust enough to support
translation into large scale trials and eventual clinical practice,”
said Clifford Hoyt, Vice President, Translational and Scientific Affairs
at Akoya Biosciences. “In addition, we’ve provided a template for other
investigative teams to use for assessing reproducibility of their
multiplex panels. The next step in this multi-site project will be to
apply this assay retrospectively to discover and develop predictive
biomarkers for PD1 and PDL1 therapies. We at Akoya are very grateful for
the significant technical and scientific contributions from
participants, who share a mission to ultimately deploy these methods for
the benefit of patients.”
Accepted abstracts will feature data from the new CODEX®
System, which can transform existing fluorescence microscopes into
high-quality multiplexed tissue imagers for more than 40 biomarkers.
Data will also be presented from the company’s new Phenoptics 2.0
platform, which includes the Vectra® Polaris™
imaging system, Opal™ detection reagents, and inForm® analysis
software. Phenoptics 2.0 now also includes the company’s proprietary
MOTiF™ technology, which acquires multispectral images on
whole-slide tissue sections using up to seven colors simultaneously, and
at speeds 20 times faster than previously possible.
Akoya’s abstracts include:
-
Multi-institutional TSA-amplified Multiplexed Immunofluorescence
Reproducibility Evaluation (MITRE Study) – Reproducibility assessment
of an automated multiplexed immunofluorescence slide staining,
imaging, and analysis workflow
Poster # 9, Section 42,
Presentation LB318
Wednesday, April 3 from 8 AM to 12 PM -
Highly multiplexed single-cell spatial analysis of tissue specimens
using CODEX®
Poster #3, Section 20, Presentation 490
Sunday,
March 31 from 1 to 5 PM -
Quantifying tumor heterogeneity and mapping complex immune cell
interactions with high-throughput, 7-color multispectral slide scans
Poster
#30, Section 6, Presentation 153
Sunday, March 31 from 1
to 5 PM
In addition, several leading pharmaceutical companies and academic
medical centers will be presenting data from studies using the company’s
multiplex immunofluorescence technology including:
-
Tumor heterogeneity and its impact on immunoprofiling data: Whole
tumor vs regions of interest (ROI) analysis of multiplex
immunofluorescence in four carcinoma types
Poster #4, Section 20,
Presentation 491
Sunday, March 31 from 1 to 5 PM -
Impact of the spatial analysis of tumor-associated lymphocytes and
tumor-associated macrophages on recurrence at early stage of non-small
cell lung carcinoma
Poster #7, Section 9, Presentation 1180
Monday,
April 1 from 8 AM to 12 PM -
Multiplexed immunofluorescence and multispectral imaging-based
quantification of tumor and immune cell populations reveals spatial
relationships in oral cavity squamous cell carcinoma
Poster #4,
Section 7, Presentation 1132
Monday, April 1 from 8 AM to 12 PM -
IL17 signaling modulates tumor microenvironment in pancreatic cancer
Poster
#29, Section 3, Presentation 4575
Wednesday, April 3 from 8 AM to
12 PM
The company will also be providing demos in its booth (#4243) on Tuesday
afternoon, April 2. For specific topics and times, see: https://www.akoyabio.com/aacr2019.
About Akoya Biosciences
Akoya Biosciences is committed to developing powerful imaging tools to
enable scientists and clinical researchers gain a better understanding
of complex diseases such as cancer. The company offers the most
comprehensive end-to-end solution for high-parameter tissue analysis
from discovery through clinical and translational research, enabling
more precise therapies for immuno-oncology and other drug development
applications. Akoya’s CODEX platform enables the assessment of more than
40 markers and is ideally suited for biomarker discovery. The company’s
Phenoptics platform provides the assay robustness and throughput
necessary for translational and clinical research required in clinical
trials. For more information, please visit https://www.akoyabio.com/.
Contacts
Nicole Litchfield
Bioscribe, Inc.
415-793-6468
nicole@bioscribe.com
or
Michelle
Linn
Bioscribe, Inc.
774-696-3803
michelle@bioscribe.com